{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:48:22Z","timestamp":1793832502137,"version":"4.6.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care: Clinics in Office Practice"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.pop.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T12:17:39Z","timestamp":1741609059000},"page":"265-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Management of Menopause Symptoms"],"prefix":"10.1016","volume":"52","author":[{"given":"Jonathan","family":"Snyder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coral","family":"Matus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Landis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Speer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.pop.2025.01.001_bib1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1089\/jwh.2012.3719","article-title":"The impact of menopausal symptoms on quality of life, productivity, and economic outcomes","volume":"22","author":"Whiteley","year":"2013","journal-title":"J Wom Health"},{"issue":"10159","key":"10.1016\/j.pop.2025.01.001_bib2","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(18)31891-9","article-title":"Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pop.2025.01.001_bib3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/13697137.2023.2258783","article-title":"The 2023 practitioner\u2019s toolkit for managing menopause","volume":"26","author":"Davis","year":"2023","journal-title":"Climacteric"},{"issue":"6","key":"10.1016\/j.pop.2025.01.001_bib4","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/GME.0000000000001282","article-title":"Menopausal hormone therapy trends before versus after 2002: impact of the women\u2019s health initiative study results","volume":"26","author":"Crawford","year":"2018","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.pop.2025.01.001_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/aje\/kwaa210","article-title":"Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50-59 Years of age","volume":"190","author":"Prentice","year":"2021","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.pop.2025.01.001_bib6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.122.061559","article-title":"Rethinking menopausal hormone therapy: for whom, what, when, and how long?","volume":"147","author":"Cho","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pop.2025.01.001_bib7","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1001\/jamainternmed.2014.1891","article-title":"Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial","volume":"174","author":"Joffe","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.pop.2025.01.001_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/GME.0000000000000978","article-title":"Clinical trials in menopause","volume":"25","author":"Marko","year":"2018","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.pop.2025.01.001_bib9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/GME.0000000000002281","article-title":"Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause","volume":"31","author":"Morga","year":"2024","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.pop.2025.01.001_bib10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/GME.0000000000000756","article-title":"Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study","volume":"24","author":"Santoro","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.pop.2025.01.001_bib11","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/1471-0528.14619","article-title":"Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause","volume":"124","author":"Sarri","year":"2017","journal-title":"BJOG"},{"issue":"5","key":"10.1016\/j.pop.2025.01.001_bib12","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/GME.0000000000001271","article-title":"Oral 17\u03b2-estradiol\/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms","volume":"26","author":"Simon","year":"2019","journal-title":"Menopause"},{"key":"10.1016\/j.pop.2025.01.001_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.maturitas.2016.05.013","article-title":"Hormone replacement therapy and the risk of endometrial cancer: a systematic review","volume":"91","author":"Sj\u00f6gren","year":"2016","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.pop.2025.01.001_bib14","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.fertnstert.2009.03.113","article-title":"Evaluation of bazedoxifene\/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile","volume":"92","author":"Lobo","year":"2009","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.pop.2025.01.001_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2217\/WHE.13.75","article-title":"Conjugated estrogen\/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause","volume":"10","author":"Mirkin","year":"2014","journal-title":"Womens Health (Lond)"},{"issue":"5","key":"10.1016\/j.pop.2025.01.001_bib16","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/AOG.0b013e31828c5974","article-title":"Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial","volume":"121","author":"Pinkerton","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.pop.2025.01.001_bib17","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/gme.0b013e3181a7df0d","article-title":"Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene\/conjugated estrogens: a randomized, controlled trial","volume":"16","author":"Pinkerton","year":"2009","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.pop.2025.01.001_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.maturitas.2009.06.006","article-title":"Bazedoxifene\/conjugated estrogens and quality of life in postmenopausal women","volume":"63","author":"Utian","year":"2009","journal-title":"Maturitas"},{"key":"10.1016\/j.pop.2025.01.001_bib19","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.2006.10.6179","article-title":"Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: southwest Oncology Group Study 9626","volume":"26","author":"Goodwin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.pop.2025.01.001_bib20","article-title":"Long-term hormone therapy for perimenopausal and postmenopausal women","volume":"1","author":"Marjoribanks","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pop.2025.01.001_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.thromres.2018.06.014","article-title":"Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis","volume":"168","author":"Rovinski","year":"2018","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.pop.2025.01.001_bib22","first-page":"767","article-title":"\u201cThe 2022 hormone therapy position statement of the North American menopause society\u201d advisory panel. The 2022 hormone therapy position statement of the North American menopause society","volume":"29","year":"2022","journal-title":"Menopause"},{"key":"10.1016\/j.pop.2025.01.001_bib23","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/gme.0b013e318247f07a","article-title":"Oral micronized progesterone for vasomotor symptoms\u2014a placebo-controlled randomized trial in healthy postmenopausal women","volume":"19","author":"Hitchcock","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.pop.2025.01.001_bib24","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.pop.2025.01.001_bib25","first-page":"454","article-title":"The Women\u2019s Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context","volume":"30","author":"Chlebowski","year":"2023","journal-title":"Menopause"},{"issue":"10204","key":"10.1016\/j.pop.2025.01.001_bib26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pop.2025.01.001_bib27","article-title":"A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.pop.2025.01.001_bib28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1042\/CS20060228","article-title":"Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy","volume":"112","author":"Prior","year":"2007","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.pop.2025.01.001_bib29","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jama.1980.03310130021021","article-title":"Oral medroxyprogesterone in the treatment of postmenopausal symptoms","volume":"244","author":"Schiff","year":"1980","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pop.2025.01.001_bib30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/01.AOG.0000441353.20693.78","article-title":"ACOG Practice Bulletin No. 141: management of menopausal symptoms","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.pop.2025.01.001_bib31","first-page":"573","article-title":"\u201cThe 2023 nonhormone therapy position statement of the North American menopause society\u201d advisory panel. The 2023 nonhormone therapy position statement of the North American menopause society","volume":"30","year":"2023","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.pop.2025.01.001_bib32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/jwh.2018.27099.mensocrec","article-title":"Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations","volume":"28","author":"Maki","year":"2019","journal-title":"J Womens Health (Larchmt)"},{"issue":"2","key":"10.1016\/j.pop.2025.01.001_bib33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/GME.0000000000000971","article-title":"Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)","volume":"25","author":"Cintron","year":"2018","journal-title":"Menopause"},{"issue":"11","key":"10.1016\/j.pop.2025.01.001_bib34","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/GME.0000000000001398","article-title":"Effects of perimenopausal transdermal estradiol on self-reported sleep, independent of its effect on vasomotor symptom bother and depressive symptoms","volume":"26","author":"Geiger","year":"2019","journal-title":"Menopause"},{"key":"10.1016\/j.pop.2025.01.001_bib35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/GME.0000000000002200","article-title":"The 2023 nonhormone therapy position statement of the North American Menopause Society","volume":"30","author":"Shufelt","year":"2023","journal-title":"Menopause"},{"key":"10.1016\/j.pop.2025.01.001_bib36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.2022.24140","article-title":"Management of menopausal symptoms","volume":"329","author":"Crandall","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.pop.2025.01.001_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.12484","article-title":"Duloxetine and escitalopram for hot flushes: efficacy and compliance in cancer survivors","volume":"27","author":"Biglia","year":"2018","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.pop.2025.01.001_bib38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.maturitas.2013.03.007","article-title":"Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopause transition","volume":"75","author":"Freeman","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.pop.2025.01.001_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.AOG.0000222383.43913.ed","article-title":"Gabapentin, estrogen, and placebo for treatment of hot flushes: a randomized controlled trial","volume":"108","author":"Reddy","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.pop.2025.01.001_bib40","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/GME.0000000000001491","article-title":"Gabapentin for the treatment of hot flushes in menopause: a meta-analysis","volume":"27","author":"Yoon","year":"2020","journal-title":"Menopause"},{"key":"10.1016\/j.pop.2025.01.001_bib41","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1200\/JCO.2009.24.5647","article-title":"Phase III, randomized, placebo-controlled evaluation of pregabalin for alleviating hot flashes","volume":"28","author":"Loprinzi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pop.2025.01.001_bib42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/AOG.0000000000005508","article-title":"Efficacy and safety of fezolinetant for the treatment of menopause-related vasomotor symptoms: a meta-analysis","volume":"143","author":"Bonga","year":"2023","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.pop.2025.01.001_bib43","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1007\/s12325-021-01900-w","article-title":"Neurokinin3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes: a systematic qualitative review","volume":"38","author":"Menown","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.pop.2025.01.001_bib44","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00192-021-04909-5","article-title":"A systematic review of neurocognitive dysfunction with overactive bladder medications","volume":"32","author":"Duong","year":"2012","journal-title":"Int Urogynecol J"},{"issue":"10","key":"10.1016\/j.pop.2025.01.001_bib45","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/GME.0000000000001812","article-title":"The Women\u2019s Study for the Alleviation of Vasomotor Symptoms (WAVS): a randomized, controlled trial of a plant-based diet and whole soybeans for postmenopausal women","volume":"28","author":"Barnard","year":"2021","journal-title":"Menopause"},{"issue":"7","key":"10.1016\/j.pop.2025.01.001_bib46","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.3390\/nu13072473","article-title":"Weight loss strategies, and the risk of skeletal muscle mass loss","volume":"13","author":"McCarthy","year":"2021","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.pop.2025.01.001_bib47","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/jcm12020548","article-title":"The efficacy of strength exercises for reducing the symptoms of menopause: a systematic review","volume":"12","author":"Capel-Alcaraz","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.pop.2025.01.001_bib49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/13697137.2020.1777965","article-title":"Cognitive behavioral therapy for menopausal symptoms","volume":"24","author":"Hunter","year":"2021","journal-title":"Climacteric"},{"issue":"1","key":"10.1016\/j.pop.2025.01.001_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2023.101819","article-title":"Non-oestrogen-based and complementary therapies for menopause","volume":"38","author":"Al Wattar","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.pop.2025.01.001_bib51","first-page":"169","article-title":"How effective the mindfulness-based cognitive behavioral therapy on quality of life in women with menopause","volume":"13","author":"John","year":"2022","journal-title":"J Midlife Health"},{"issue":"1","key":"10.1016\/j.pop.2025.01.001_bib52","first-page":"28","article-title":"Managing menopausal symptoms: common questions and answers","volume":"108","author":"Chang","year":"2023","journal-title":"Am Fam Physician"},{"issue":"7","key":"10.1016\/j.pop.2025.01.001_bib53","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/GME.0000000000000836","article-title":"An Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors: results of a pilot study","volume":"24","author":"Atema","year":"2017","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.pop.2025.01.001_bib54","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10549-019-05410-w","article-title":"Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms","volume":"178","author":"Verbeek","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.pop.2025.01.001_bib55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/00207144.2021.1919520","article-title":"Hypnosis intervention for sleep disturbance: determination of optimal dose and method of delivery for postmenopausal women","volume":"69","author":"Elkins","year":"2021","journal-title":"Int J Clin Exp Hypn"},{"key":"10.1016\/j.pop.2025.01.001_bib56","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40064-015-0808-y","article-title":"A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients","volume":"4","author":"Drewe","year":"2015","journal-title":"SpringerPlus"},{"issue":"3","key":"10.1016\/j.pop.2025.01.001_bib57","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jsxm.2017.01.010","article-title":"The Women\u2019s EMPOWER Survey: identifying women\u2019s perceptions on vulvar and vaginal atrophy and its treatment","volume":"14","author":"Kingsberg","year":"2017","journal-title":"J Sex Med"},{"issue":"8","key":"10.1016\/j.pop.2025.01.001_bib58","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/09513590.2021.1931100","article-title":"Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy","volume":"37","author":"P\u00e9rez-L\u00f3pez","year":"2021","journal-title":"Gynecol Endocrinol"},{"issue":"4 Suppl 1","key":"10.1016\/j.pop.2025.01.001_bib59","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0090-4295(03)00676-9","article-title":"The role of estrogens in female lower urinary tract dysfunction","volume":"62","author":"Robinson","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.pop.2025.01.001_bib60","first-page":"CD001405","article-title":"Oestrogen therapy for urinary incontinence in post-menopausal women","volume":"10","author":"Cody","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.pop.2025.01.001_bib61","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/SPV.0000000000000749","article-title":"Vaginal estrogen for the prevention of recurrent urinary tract infection in postmenopausal women: a randomized clinical trial","volume":"27","author":"Ferrante","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"10","key":"10.1016\/j.pop.2025.01.001_bib62","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1210\/jc.2005-2378","article-title":"Comparison of methods to measure low serum estradiol levels in postmenopausal women","volume":"91","author":"Lee","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.pop.2025.01.001_bib63","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/GME.0000000000000470","article-title":"Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women","volume":"22","author":"Portman","year":"2015","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.pop.2025.01.001_bib64","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/gme.0b013e31826d36ba","article-title":"The Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.pop.2025.01.001_bib65","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/09513590.2017.1370645","article-title":"Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome: outcome after 6 months of treatment with ospemifene","volume":"34","author":"Schiavi","year":"2018","journal-title":"Gynecol Endocrinol"},{"issue":"7","key":"10.1016\/j.pop.2025.01.001_bib66","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/GME.0000000000001138","article-title":"The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): international Society for the Study of Women\u2019s Sexual Health (ISSWSH) expert consensus panel review","volume":"25","author":"Simon","year":"2018","journal-title":"Menopause"},{"issue":"7","key":"10.1016\/j.pop.2025.01.001_bib67","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/ijd.14370","article-title":"The efficacy and use of finasteride in women: a systematic review","volume":"58","author":"Hu","year":"2019","journal-title":"Int J Dermatol"},{"issue":"7","key":"10.1016\/j.pop.2025.01.001_bib68","doi-asserted-by":"crossref","first-page":"813","DOI":"10.17219\/acem\/157990","article-title":"A systematic review of clinical trials using single or combination therapy of oral or topical finasteride for women in reproductive age and postmenopausal women with hormonal and nonhormonal androgenetic alopecia","volume":"32","author":"Nobari","year":"2023","journal-title":"Adv Clin Exp Med"},{"issue":"5","key":"10.1016\/j.pop.2025.01.001_bib69","first-page":"CD007628","article-title":"Interventions for female pattern hair loss","volume":"2016","author":"van Zuuren","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.pop.2025.01.001_bib70","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1210\/jc.2018-02548","article-title":"Female pattern hair loss and androgen excess: a report from the multidisciplinary androgen excess and PCOS committee","volume":"104","author":"Carmina","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.pop.2025.01.001_bib71","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/jocd.15910","article-title":"The relative effect of monotherapy with 5-alpha reductase inhibitors and minoxidil for female pattern hair loss: a network meta-analysis study","volume":"23","author":"Gupta","year":"2024","journal-title":"J Cosmet Dermatol"}],"container-title":["Primary Care: Clinics in Office Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095454325000119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095454325000119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T20:13:59Z","timestamp":1747944839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095454325000119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0095454325000119"],"URL":"https:\/\/doi.org\/10.1016\/j.pop.2025.01.001","relation":{},"ISSN":["0095-4543"],"issn-type":[{"value":"0095-4543","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Menopause Symptoms","name":"articletitle","label":"Article Title"},{"value":"Primary Care: Clinics in Office Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pop.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}